This Biotech Stock Is Surging 66% on Surprise Good News From FDA -- Barrons.com

Dow Jones06-17

By Mackenzie Tatananni

Gene therapy company uniQure has faced a brutal uphill battle to commercialize its experimental treatment for Huntington's disease, but its outlook suddenly has brightened.

Shares of the Amsterdam-based biopharmaceutical company surged 66% on Wednesday after uniQure said it would seek regulatory approval to bring its gene therapy candidate, AMT-130, to market.

The Food and Drug Administration has cleared uniQure to submit a Biologics License Application for the drug, the company said. A BLA is a formal request to market and distribute a medical product derived from living organisms across state lines.

The FDA's position is an about-face. Months ago, the agency declared that uniQure's Phase I and II data wasn't enough to support a BLA, and as recently as March the agency suggested running another study. In a recent meeting, however, the FDA reversed course, telling uniQure that a three-year analysis of those same Phase I and II trials can now serve as the primary basis for their application.

Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

June 17, 2026 10:10 ET (14:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2644573744?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-17 22:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2644573744","market":"us","top_or_hot":-1,"title":"This Biotech Stock Is Surging 66% on Surprise Good News From FDA -- Barrons.com","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Mackenzie Tatananni \n</p>\n<p>\n  Gene therapy company uniQure has faced a brutal uphill battle to commercialize its experimental treatment for Huntington's disease, but its outlook suddenly has brightened. \n</p>\n<p>\n  Shares of the Amsterdam-based biopharmaceutical company surged 66% on Wednesday after uniQure said it would seek regulatory approval to bring its gene therapy candidate, AMT-130, to market. \n</p>\n<p>\n  The Food and Drug Administration has cleared uniQure to submit a Biologics License Application for the drug, the company said. A BLA is a formal request to market and distribute a medical product derived from living organisms across state lines. \n</p>\n<p>\n  The FDA's position is an about-face. Months ago, the agency declared that uniQure's Phase I and II data wasn't enough to support a BLA, and as recently as March the agency suggested running another study. In a recent meeting, however, the FDA reversed course, telling uniQure that a three-year analysis of those same Phase I and II trials can now serve as the primary basis for their application. \n</p>\n<p>\n  Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 17, 2026 10:10 ET (14:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Biotech Stock Is Surging 66% on Surprise Good News From FDA -- Barrons.com</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Biotech Stock Is Surging 66% on Surprise Good News From FDA -- Barrons.com\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-17 22:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Mackenzie Tatananni \n</p>\n<p>\n  Gene therapy company uniQure has faced a brutal uphill battle to commercialize its experimental treatment for Huntington's disease, but its outlook suddenly has brightened. \n</p>\n<p>\n  Shares of the Amsterdam-based biopharmaceutical company surged 66% on Wednesday after uniQure said it would seek regulatory approval to bring its gene therapy candidate, AMT-130, to market. \n</p>\n<p>\n  The Food and Drug Administration has cleared uniQure to submit a Biologics License Application for the drug, the company said. A BLA is a formal request to market and distribute a medical product derived from living organisms across state lines. \n</p>\n<p>\n  The FDA's position is an about-face. Months ago, the agency declared that uniQure's Phase I and II data wasn't enough to support a BLA, and as recently as March the agency suggested running another study. In a recent meeting, however, the FDA reversed course, telling uniQure that a three-year analysis of those same Phase I and II trials can now serve as the primary basis for their application. \n</p>\n<p>\n  Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com \n</p>\n<p>\n   This content was created by Barron's, which is operated by Dow Jones &amp; Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 17, 2026 10:10 ET (14:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2644573744","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2644573744","pubTimestamp":1781705400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Gene therapy company uniQure has faced a brutal uphill battle to commercialize its experimental treatment for Huntington's disease, but its outlook suddenly has brightened.Shares of the Amsterdam-based biopharmaceutical company surged 66% on Wednesday after uniQure said it would seek regulatory approval to bring its gene therapy candidate, AMT-130, to market.The Food and Drug Administration has cleared uniQure to submit a Biologics License Application for the drug, the company said. A BLA is a formal request to market and distribute a medical product derived from living organisms across state lines.The FDA's position is an about-face. Months ago, the agency declared that uniQure's Phase I and II data wasn't enough to support a BLA, and as recently as March the agency suggested running another study. In a recent meeting, however, the FDA reversed course, telling uniQure that a three-year analysis of those same Phase I and II trials can now serve as the primary basis for their applicatio","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","QURE":"uniQure N.V.","BK4585":"ETF&股票定投概念","XBI":"SPDR S&P Biotech ETF","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4581":"高盛持仓","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LABU":"三倍做多标普生物-Direxion"},"translate_title":"FDA传来意外好消息，该生物科技股飙升66%--Barrons.com","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"QURE":0.9,"XBI":1.5},"content_text":"By Mackenzie Tatananni \n\n\n  Gene therapy company uniQure has faced a brutal uphill battle to commercialize its experimental treatment for Huntington's disease, but its outlook suddenly has brightened. \n\n\n  Shares of the Amsterdam-based biopharmaceutical company surged 66% on Wednesday after uniQure said it would seek regulatory approval to bring its gene therapy candidate, AMT-130, to market. \n\n\n  The Food and Drug Administration has cleared uniQure to submit a Biologics License Application for the drug, the company said. A BLA is a formal request to market and distribute a medical product derived from living organisms across state lines. \n\n\n  The FDA's position is an about-face. Months ago, the agency declared that uniQure's Phase I and II data wasn't enough to support a BLA, and as recently as March the agency suggested running another study. In a recent meeting, however, the FDA reversed course, telling uniQure that a three-year analysis of those same Phase I and II trials can now serve as the primary basis for their application. \n\n\n  Write to Mackenzie Tatananni at mackenzie.tatananni@barrons.com \n\n\n   This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 17, 2026 10:10 ET (14:10 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2644573744","isCrawlerRequest":true}